Connection

Co-Authors

This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and RICHARD E CHAMPLIN.
Connection Strength

0.616
  1. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.079
  2. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64.
    View in: PubMed
    Score: 0.077
  3. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.060
  4. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
    View in: PubMed
    Score: 0.053
  5. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9.
    View in: PubMed
    Score: 0.051
  6. Can we cure refractory Hodgkin's lymphoma with transplantation? Bone Marrow Transplant. 2021 01; 56(1):278-281.
    View in: PubMed
    Score: 0.046
  7. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.042
  8. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.
    View in: PubMed
    Score: 0.041
  9. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.
    View in: PubMed
    Score: 0.032
  10. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.
    View in: PubMed
    Score: 0.028
  11. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.
    View in: PubMed
    Score: 0.026
  12. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.
    View in: PubMed
    Score: 0.021
  13. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995 May; 17(5-6):427-33.
    View in: PubMed
    Score: 0.016
  14. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001 Sep 01; 19(17):3766-70.
    View in: PubMed
    Score: 0.012
  15. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
    View in: PubMed
    Score: 0.012
  16. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.011
  17. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.